Matching trials
2,411 results
- NKTR-214Independent statistical analysis of A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval,…
- NMDA Receptors in Motor Learning in Humans: Complete Statistical AnalysisIndependent statistical analysis of NMDA Receptors in Motor Learning in Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02082912).
- no-cryIndependent statistical analysis of Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NOLANIndependent statistical analysis of NOLAN: Naproxen or Loratadine and Neulasta: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01712009).
- Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma: primary endpoint…
- Non-opioids for Analgesia After Adenotonsillectomy in Children: Complete Statistical AnalysisIndependent statistical analysis of Non-opioids for Analgesia After Adenotonsillectomy in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03618823).
- Normobaric Hyperoxia for Intracerebral Hemorrhage: Complete Statistical AnalysisIndependent statistical analysis of Normobaric Hyperoxia for Intracerebral Hemorrhage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04144868).
- Norovirus Bivalent-Vaccine Efficacy Study: Complete Statistical AnalysisIndependent statistical analysis of Norovirus Bivalent-Vaccine Efficacy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01609257).
- NOVA2Independent statistical analysis of Inhaled Nitric Oxide and Neuroprotection in Premature Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00515281).
- Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04447846).
- Novel Management of Airway Protection in Parkinson’s Disease: A Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NOVEMBERIndependent statistical analysis of Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies: Complete Statistical AnalysisIndependent statistical analysis of NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NRRIndependent statistical analysis of Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- NSCLCIndependent statistical analysis of Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: Complete Statistical AnalysisIndependent statistical analysis of NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nutraceutical Efficacy for rUTI: Complete Statistical AnalysisIndependent statistical analysis of Nutraceutical Efficacy for rUTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03395288).
- O-BMTIndependent statistical analysis of Onsite Buprenorphine Treatment at Syringe Exchange Programs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03150173).
- OASISIndependent statistical analysis of Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04720664).
- Obatoclax for Systemic Mastocytosis: Complete Statistical AnalysisIndependent statistical analysis of Obatoclax for Systemic Mastocytosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00918931).
- Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- OCEANIndependent statistical analysis of Randomized Study of Obicetrapib in Combination With Ezetimibe: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04770389).
- Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…
- Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01258933).
- Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study: Complete Statistical AnalysisIndependent statistical analysis of Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03570476).
- Olaparib in Adults With Recurrent/Metastatic Ewing’s Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01583543).
- OLAPCOIndependent statistical analysis of OLAParib COmbinations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02576444).
- OLEIndependent statistical analysis of Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- OLE2Independent statistical analysis of An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10): Complete Statistical AnalysisIndependent statistical analysis of Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01294241).
- OLFUS-VIPESIndependent statistical analysis of Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Omalizumab in the Treatment of Peanut Allergy: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in the Treatment of Peanut Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00949078).
- Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits: Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00511810).
- ONC201 in Adults With Recurrent H3 K27M-mutant Glioma: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Adults With Recurrent H3 K27M-mutant Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03295396).
- ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Online Caregiver Psychoeducation and Support for Alzheimer’s: Complete Statistical AnalysisIndependent statistical analysis of Online Caregiver Psychoeducation and Support for Alzheimer's: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00416078).
- ONPEDIndependent statistical analysis of Oral Naltrexone In Pediatric Eating Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05073679).
- ONTAKIndependent statistical analysis of A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel: Complete Statistical AnalysisIndependent statistical analysis of Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02946788).
- Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with…
- Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen: Complete Statistical AnalysisIndependent statistical analysis of Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…